Menta Capital’s Teva Pharmaceutical Industries Limited TEVA Stock Holding History

Menta Capital’s Portfolio TEVA Stock Details TEVA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q2	–	Sell	-56,400	Closed	-$884K	–	592
2019 Q1	$884K	Buy	+56,400	New	+$995K	0.39%	74
2016 Q4	–	Sell	-213,408	Closed	-$9.8M	–	966
2016 Q3	$9.8M	Buy	+213,408	New	+$11.1M	0.94%	2
2016 Q2	–	Sell	-140,300	Closed	-$7.51M	–	979
2016 Q1	$7.51M	Buy	140,300 +61,500	+78%	+$3.61M	1.03%	4
2015 Q4	$5.17M	Sell	78,800 -8,400	-10%	-$519K	0.66%	7
2015 Q3	$4.92M	Buy	87,200 +14,000	+19%	+$908K	0.78%	1
2015 Q2	$4.33M	Buy	73,200 +21,400	+41%	+$1.32M	0.71%	1
2015 Q1	$3.23M	Buy	51,800 +21,400	+70%	+$1.24M	0.42%	46
2014 Q4	$1.75M	Buy	30,400 +6,200	+26%	+$345K	0.25%	119
2014 Q3	$1.3M	Buy	+24,200	New	+$1.28M	0.21%	142

Other funds holding TEVA

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return

Berkshire Hathaway Omaha, Nebraska $299B AUM 27.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Abrams Capital Management Boston, Massachusetts $5.48B AUM 3.63% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Menta Capital's TEVA Position: Q2 2019 in Review

Menta Capital sold out of Teva Pharmaceutical Industries Limited (TEVA) in Q2 2019, closing a stake of 56,400 shares — an estimated $884K sold.

Menta Capital first reported a position in TEVA in Q3 2014 and held it in 9 quarters. The position peaked at $9.8M in Q3 2016. 452 funds tracked by Wall St. Rank hold TEVA as of Q2 2019.

Menta Capital reported no remaining Teva Pharmaceutical Industries Limited position as of Q2 2019 after selling out during the quarter.
Menta Capital sold 56,400 Teva Pharmaceutical Industries Limited shares in Q2 2019, an estimated $884K.
Menta Capital first reported a position in Teva Pharmaceutical Industries Limited in Q3 2014 and held it in 9 quarters.
Menta Capital's Teva Pharmaceutical Industries Limited position peaked at $9.8M in Q3 2016.
452 funds tracked by Wall St. Rank held Teva Pharmaceutical Industries Limited as of Q2 2019.

Based on Menta Capital's 13F filing for Q2 2019, filed 7 Aug 2019.